

Exploring Disease Manifestations and Influencing Factors in Acute and Chronic Hepatitis B

Napoleon Bellua Sam, MSc, PhD

Department of Medical Research and Innovation, School of Medicine,
University for Development Studies, Tamale, Northern Region, Ghana

Abena Serwaa Ofori, MEd, PhD

Department of Nursing, Kokofu Nursing and Midwifery Training College,
Kokofu, Ashanti Region, Ghana

Saeed Folorunsho Majeed, MPhil

Department of Biological Science, Faculty of Biosciences,
University for Development Studies, Tamale, Northern Region, Ghana

[Doi:10.19044/esj.2024.v20n33p59](https://doi.org/10.19044/esj.2024.v20n33p59)

Submitted: 14 August 2024

Accepted: 06 November 2024

Published: 30 November 2024

Copyright 2024 Author(s)

Under Creative Commons CC-BY 4.0

OPEN ACCESS

Cite As:

Sam N.B., Ofori A.S. & Majeed S.F. (2024). *Exploring Disease Manifestations and Influencing Factors in Acute and Chronic Hepatitis B*. European Scientific Journal, ESJ, 20 (33), 59. <https://doi.org/10.19044/esj.2024.v20n33p59>

Abstract

Scope and Aims: The investigation of disease manifestations and influencing factors in both acute hepatitis B (AHB) and chronic hepatitis B (CHB) remains limited, with varying results. This study aimed to explore the factors influencing AHB and CHB and their disease manifestations within a Ghanaian population, with the goal of developing a control strategy. **Methods:** A retrospective study was conducted on 569 admitted hepatitis B cases. Demographic data and disease manifestations were compared between AHB and CHB patients. Logistic regression and correlation analyses were employed to identify the factors influencing the progression of the disease. **Results:** Significant differences were observed between AHB and CHB patients in terms of median age and hospitalization duration. Variations in age, gender, education level, and occupational distributions were statistically significant ($P < 0.05$) between the two groups. Symptoms such as fever, nausea, polydipsia, palpitation, anicteric presentation, anorexia, and itching were less common in CHB patients ($P < 0.05$), while abdominal pain, jaundice, and enlarged liver were more frequent ($P < 0.05$). CHB patients exhibited significantly higher

levels of aspartate aminotransferase, viral load, bilirubin, prothrombin time, partial thromboplastin time, HBeAg, albumin, abdominal ultrasound findings, and globin ($P < 0.05$), while HBsAg and liver function test levels were significantly lower ($P < 0.05$) in CHB patients compared to AHB patients. Logistic regression identified age, gender, occupation, education level, and hospitalization duration as significant influencing factors. **Conclusion:** Males and the adult population represented a higher proportion of CHB patients, with a significant association between CHB and elevated clinical and laboratory characteristics. Age, gender, occupation, education level, and hospitalization duration were established as key influencing factors in the progression of hepatitis B.

Keywords: Acute hepatitis B, chronic hepatitis B, disease manifestations, control strategy, logistics regression

Introduction

Hepatitis B (HB) is a viral infectious disease that could manifest as either acute or chronic and poses a significant global health challenge. It was estimated that between 500,000 to 1.2 million people died annually due to chronic hepatitis, cirrhosis, and hepatocellular carcinoma (Lavanchy et al., 2004). HB is an inflammation of the liver caused by the Hepatitis B virus (HBV), which is transmitted through contact with infected body fluids, including unsafe sexual contact, blood transfusions, mother-to-child transmission during birth, cuts, and contaminated needles (RIVM, 2013). HBV could remain infectious on surfaces for up to a week (WHO, 2002). In regions with a high prevalence of HBV, such as Sub-Saharan Africa and East Asia, mother-to-child transmission and person-to-person contact during childhood were common. In contrast, transmission in wealthier regions like Western Europe and North America occurred primarily through unsafe sexual contact and injection drug use (WHO, 2013).

There were several clinical stages of HB infection. The time between infection and symptom onset, known as the incubation period, typically ranges from 6 to 26 weeks, depending on the viral dose (RIVM, 2013). Acute Hepatitis B (AHB) could present with symptoms such as fatigue, fever, joint pain, and jaundice, though many cases were asymptomatic (RIVM, 2013). Approximately two-thirds of HBV-infected individuals experienced an asymptomatic acute infection, with most recovering within three to four months and developing lifetime immunity (van Ballegooijen et al., 2009). However, about 1% of AHB cases progressed to fulminant hepatitis, a severe and often fatal condition (van de Laar et al., 2000).

Chronic Hepatitis B (CHB) occurs when acute infection persists for more than six months, affecting roughly 5% of all cases (van de Laar et al., 2000), although more recent studies indicated higher rates among specific populations, such as men who have sex with men (23%) and drug users (28%) (van Houdt et al., 2012). Chronic infection could lead to severe complications such as cirrhosis and hepatocellular carcinoma, with 25-35% of chronic patients progressing to these conditions and 15-25% dying prematurely as a result (RIVM, 2013). The risk of developing CHB was influenced by age, immune status, and gender, with newborns having a 70-90% chance of progressing to chronic infection compared to 25-50% of children under five and 5-10% of older children and adults. Men were also six times more likely than women to develop CHB. In cases of reduced immunity, HBV replication continued without severe symptoms, leading to chronic carrier status (van de Laar et al., 2000).

Changes in laboratory parameters could sometimes predict HBV infection in patients (Kumar et al., 2008). Preventing, controlling, and treating HBV and its complications requires comprehensive public health strategies. Although treatment for CHB aimed to improve quality of life, many patients, especially those on interferon therapy, experienced fatigue, low self-esteem, and reduced daily functioning (Asadi Noghabi et al., 2010). Several studies explored the risk factors for HBV in various populations, examining their role in disease progression and outcomes. However, the severity of complications is often correlated with clinical and laboratory manifestations (Kumar et al., 2008; Salimi et al., 2014).

In Ghana, the prevalence of HBV infection was high (Averhoff et al., 2016; Howell et al., 2014) and required greater public health attention (Mkandawire et al., 2013; Owusu-Ansah, 2014). Ghana was considered one of the regions with a high prevalence of chronic HBV infection (Averhoff et al., 2016; Howell et al., 2014), with studies estimating a prevalence rate of 10-15% (GhanaWeb, 2013; Teye, 2015). Other studies reported HBV prevalence rates of 6.7-11% among blood donors (Dongdem et al., 2012; Walana et al., 2014), 6.4% among pregnant women (Acquaye et al., 1994), and 15.6% among children (Martinson et al., 1996). A three-year retrospective study among 3,402 blood donors showed an overall seroprevalence of Hepatitis B surface antigen at 9.6% (Walana et al., 2014). Despite these findings, no study specifically examined the influencing factors and disease manifestations of both AHB and CHB patients in Ghana. This study, therefore, aimed to investigate these factors in a Ghanaian population to inform a control strategy for Hepatitis B.

Methods

Patients

This eight-year retrospective study recruited 569 patients with HB cases from Tamale Teaching Hospital, Ghana. Patients who had tested positive for HBV which had developed into either acute or chronic infections were included in this study. Patients who were diagnosed with liver disease or any other disease other than hepatitis B, such as hepatitis C and autoimmune hepatitis were excluded. The required demographic data on HB were searched from patients' folders at the hospital. This study sought to categorize occupations into children, students, traders, fishermen/farmers, housewives, businessmen, professionals (teachers, health professionals, etc.) and others (unskilled labour, unemployed, etc.). The outcome of the HB at the hospital was based on whether the patient was discharged or died. This study also classified educational levels into illiterate (none), primary, junior high school (JHS), senior high school including technical/vocational (SHS) and tertiary. The hospitalization duration was noted as the date the patient was admitted to the date the patient was eventually discharged or died at the hospital. The hospital approved this study and since data were analysed and reported anonymously, there was no need to request the consent of the participants involved.

Collection of Clinical and Laboratory, Statistical Analysis, Influencing Factors of Acute and Chronic HB

Qualified medical doctors (gastroenterologist) reviewed and extracted clinical and laboratory features from patients' records. The American Association for the Study of Liver Disease (AASLD) practice guidelines regarding the diagnostic criteria were followed to determine the disease manifestations of the patients (AASLD, 2011). Clinical manifestations such as jaundice, enlarged liver, variceal bleeding, abdominal pain, icterus, portal hypertension, anicteric, constipation, dark stool, fatigue, nausea, fever, anorexia, itching, palpitation, polyuria, and polydipsia were selected for this study. Laboratory manifestations were revealed mainly through the following; liver function test (LFT), renal function test (RFT), abdominal ultrasound test (USG), aspartate aminotransferase (AST) test, alanine aminotransferase (ALT) test, Viral load (HBV DNA- using Polymerase Chain Reaction) test, Hepatitis B surface antigen (HBsAg) test, hepatitis B e-antigen (HBeAg) test and lipid profile. The laboratory features were recorded as AST, ALT, prothrombin time (PT), partial thromboplastin time (PTT), bilirubin, globulin, albumin, hemoglobin, abdominal USG, RFT, LFT, HBsAg, HBeAg, viral load (HBV DNA) concentration and total cholesterol.

SPSS version 21 was used to analyze the data. Continuous variables were described as median with inter-quartile range (median (IQR)) for skewed

distributions. Categorical variables were also indicated in percentages. Comparisons between continuous variables were conducted using the Student's t-test or independent-samples Mann-Whitney U test. The chi-square test or Fisher's exact test and Spearman correlation were used for the categorical variables. Binary logistic regression was used to find out the influencing factors of HB diagnosis and the results were recorded. Odds ratios (OR) with 95% confidence intervals (CI) were used to display the results.

The clinical and laboratory features as well as demographic characteristics were compared between AHB and CHB patients. $P < 0.05$ was used to indicate the significance level.

A logistic regression model was employed to gain a deeper comprehension of the variables impacting the advancement of Hepatitis B into its acute and chronic stages. With the use of this model, we were able to examine the relationship between a number of predictor variables (including age, gender, occupation, educational level, hospitalization and location) and the binary outcome of the Hepatitis B categorization (Acute versus Chronic). The logistic regression equation is defined as follows:

$$\ln \ln \left(\frac{P}{1 - P} \right) = \beta_0 + \beta_1 X_1 + \beta_2 X_2 \dots \dots \dots + \beta_n X_n$$

Where:

- P is the probability of a patient having CHB.
- X_1, X_2, \dots, X_n are the predictor variables (including age, gender, occupation, educational level, hospitalization and location).
- β_0 is the intercept of the model.
- $\beta_1, \beta_2, \dots, \beta_n$ are the coefficients representing the impact of each predictor on the probability of CHB.

Results

A total of 569 patients were diagnosed with the majority being AHB representing 355(62.4%) and a little above one-third (214(37.6%)) constituting CHB patients. A greater number of patients 455(80%), who visited the hospital facility with HB cases within the study period were discharged leaving 114(20%) dead at the facility. Most of the patients 204(35.9%) who presented cases of HB to the Tamale Teaching Hospital were farmers/fishermen. Persons belonging to the business community recorded fewer cases 11(1.9%). HB cases were high 388(68.2) among patients without formal education but fewer among patients with at least primary to tertiary education (31.8%). The Northern region registered the highest number

of patients 470(82.6%) who visited the facility. Hardly did the hospital receive HB patients from Oti region 2(0.4%) (Table 1).

Table 1: Demographic characteristics

| Variables | Frequency (%) |
|----------------------------|---------------|
| Disease Outcome | |
| Dead | 114(20) |
| Discharge | 455(80) |
| Hepatitis Diagnosis | |
| Acute | 355(62.4) |
| Chronic | 214(37.6) |
| Educational level | |
| None | 388(68.2) |
| Primary | 38(6.7) |
| JHS | 17(3.0) |
| SHS | 44(7.7) |
| Tertiary | 82(14.4) |
| Occupation | |
| Child | 34(6.0) |
| Student | 67(11.8) |
| Trader/stop attendant | 70(12.3) |
| Fishermen/Farmer | 204(35.9) |
| Housewife | 19(3.3) |
| Businessman | 11(1.9) |
| Professional | 72(12.7) |
| Others | 92(16.2) |
| Residence(region) | |
| Northern | 470(82.6) |
| Savanna | 31(5.4) |
| Upper East | 41(7.2) |
| Upper West | 6(1.1) |
| North East | 19(3.3) |
| Oti | 2(0.4) |

There was a significant difference in median age for acute and chronic patients (32 (24, 42) vs. 35 (28, 45) years, ($P < 0.05$). The hospitalization duration was also significant between acute (6(4,9)) and chronic (7(4,11)) HB patients. It implied that the chronic HB patients spent more days at the hospital than the acute patients. The variations in age distribution between the acute and chronic patients were statistically significant ($P < 0.05$). The majority of the chronic HB patients were males (89.3%); however, females constituted the highest number of acute HB patients. More CHB patients (25.2%) died compared to the AHB, though, the majority of the AHB (83.1%) patients were discharged from the hospital. A higher number of acute HB patients had primary, JHS and no education but less number for SHS and tertiary education compared to the CHB patients ($P < 0.05$). There were more chronic HB patients as students, traders, businessmen, professionals, and others but less as children, fishermen/farmers, and housewives compared to the acute. Most

acute HB patients lived in the Northern region (84.4%), meanwhile, both acute and chronic HB patients hardly came from the Oti region. The demographic characteristics of the two groups are summarized in Table 2.

Table 2: Demographic features on disease diagnosis

| Variables | Hepatitis B Diagnosis | | P-value |
|-----------------------------|-----------------------|-------------|---------|
| | Acute (%) | Chronic (%) | |
| Age(years) | | | 0.005* |
| < 5 | 12(3.4) | 1(0.5) | |
| 5 to < 15 | 22(6.2) | 3(1.4) | |
| 15 to < 50 | 267(75.2) | 175(81.8) | |
| 50 and above | 54(15.2) | 35(16.4) | |
| Gender | | | 0.005* |
| Female | 70(19.7) | 23(10.7) | |
| Male | 285(80.3) | 191(89.3) | |
| Hospitality duration | 6(4,9) | 7(4,11) | 0.003* |
| Disease Outcome | | | 0.016* |
| Dead | 60(16.9) | 54(25.2) | |
| Discharge | 295(83.1) | 160(74.8) | |
| Educational level | | | 0.000* |
| None | 256(72.1) | 132(61.7) | |
| Primary | 24(6.8) | 14(6.5) | |
| JHS | 12(3.4) | 5(2.3) | |
| SHS | 12(3.4) | 32(15.0) | |
| tertiary | 51(14.4) | 31(14.5) | |
| Occupation | | | 0.000* |
| Child | 30(8.5) | 4(1.9) | |
| Student | 41(11.5) | 26(12.1) | |
| Trader/stop attendant | 43(12.1) | 27(12.6) | |
| Fishermen/Farmer | 138(38.9) | 66(30.8) | |
| Housewife | 16(4.5) | 3(1.4) | |
| Businessman | 4(1.1) | 7(3.3) | |
| Professional | 44(12.4) | 28(13.1) | |
| Others | 39(11.0) | 53(24.8) | |
| Residence(region) | | | 0.603 |
| Northern | 301(84.8) | 169(79.0) | |
| Savanna | 16(4.5) | 15(7.0) | |
| Upper East | 24(6.8) | 17(7.9) | |
| Upper West | 3(0.8) | 3(1.4) | |
| North East | 10(2.8) | 9(4.2) | |
| Oti | 1(0.3) | 1(0.5) | |

*Indicates significant association ($p < 0.05$); JHS, junior high school; SHS, Senior high school

Fever, nausea, polydipsia, palpitation, anicteric, anorexia and itching were less frequent, while, abdominal pain, jaundice and enlarged liver were more frequent in chronic HB than in acute HB patients. No significant differences were observed in the other clinical features between AHB and CHB patients ($P > 0.05$). The AST, viral load, bilirubin, PT, PTT, and HBeAg levels were significantly higher in chronic HB than in acute HB patients.

Serum albumin, abdominal USG, and globin were lower but LFT and HBsAg were higher in AHB than in CHB patients ($P < 0.05$). ALT, hemoglobin, RFT and total cholesterol levels were similar between AHB and CHB patients ($P > 0.05$). The prevalence of fever, nausea, polydipsia, palpitation, anicteric, anorexia, and itching correlated negatively with disease diagnosis (all $r_s =$ negative, $P < 0.05$) but abdominal pain, jaundice and enlarged liver correlated positively (all $r_s =$ positive, $P < 0.05$). AST, viral load, HBeAg, PT, PTT, bilirubin, albumin, abdominal USG, and globulin also correlated positively (all $r_s =$ positive, $P < 0.05$) with disease diagnosis whereas HBsAg and LFT correlated negatively (all $r_s =$ negative, $P < 0.05$) with disease diagnosis. There was no significant difference in the other laboratory or clinical characteristics between acute and chronic HB patients ($P > 0.05$). Clinical and laboratory characteristics of HB diagnosis are detailed in Table 3.

Table 3: Comparison of clinical and laboratory characteristics and disease diagnosis

| Disease manifestations | Disease Diagnosis | | P | r_s value |
|------------------------|-------------------|-------------|--------|-------------|
| | Acute (%) | Chronic (%) | | |
| Abdominal Pain | 292(82.3) | 206(96.3) | 0.000* | 0.205* |
| Jaundice | 275(77.5) | 198(90.2) | 0.000* | 0.161* |
| Fever | 76(21.4) | 23(10.7) | 0.001* | -0.136* |
| Nausea | 50(14.1) | 12(5.6) | 0.002* | -0.132* |
| Constipation | 30(8.5) | 13(6.1) | 0.299 | NS |
| Vericeal bleed | 34(9.6) | 32(15.0) | 0.052 | NS |
| Icterus | 32(9.0) | 28(13.1) | 0.126 | NS |
| Enlarge Liver | 38(10.7) | 44(20.6) | 0.001* | 0.136* |
| Polyuria | 29(8.2) | 12(5.6) | 0.252 | NS |
| Fatigue | 18(5.1) | 15(7.0) | 0.338 | NS |
| Polydipsia | 13(3.7) | 2(0.9) | 0.049* | -0.082* |
| Palpitation | 19(5.4) | 4(1.9) | 0.041* | -0.086* |
| Anicteric | 13(3.7) | 2(0.9) | 0.049* | -0.082* |
| Anorexia | 19(5.4) | 2(0.9) | 0.007* | -0.114* |
| Dark stool | 24(6.8) | 7(3.3) | 0.076 | NS |
| Portal Hypertension | 14(3.9) | 4(1.9) | 0.171 | NS |
| Itching | 19(5.4) | 2(0.9) | 0.007* | -0.114* |
| High AST | 108(30.4) | 116(54.2) | 0.000* | 0.236* |
| High ALT | 202(56.9) | 128(59.8) | 0.495 | NS |
| Viral Load | 8(2.3) | 28(13.1) | 0.000* | 0.216* |
| HBeAg | 3(0.8) | 97(45.3) | 0.000* | 0.566* |
| HBsAg | 65(18.3) | 13(6.1) | 0.000* | -0.172* |
| PT | 285(80.3) | 199(93.0) | 0.000* | 0.173* |
| PTT | 285(80.3) | 199(93.3) | 0.000* | 0.173* |
| High Bilirubin | 269(75.8) | 194(90.7) | 0.000* | 0.185* |
| Low albumin | 264(74.4) | 193(90.2) | 0.000* | 0.193* |
| Low haemoglobin | 90(25.4) | 62(29.0) | 0.344 | NS |
| Abdominal USG | 41(11.5) | 56(26.2) | 0.000* | 0.188* |
| Low globulin | 74(20.8) | 77(36.0) | 0.000* | 0.166* |
| RFT | 38(10.7) | 18(8.4) | 0.374 | NS |
| Total Cholesterol | 25(7.0) | 17(7.9) | 0.690 | NS |
| LFT | 10(2.8) | 0(0) | 0.016* | -0.104* |

*Indicates significant association ($p < 0.05$); NS, not significant; HB, hepatitis; r_s , correlation coefficient; RFT, renal function test; LFT, liver function test; HBsAg, Hepatitis B surface antigen; HBeAg, hepatitis B e-antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; PTT, partial thromboplastin time.

Influencing factors of acute and chronic HB

From Table 4, Binary logistic regression was conducted to ascertain the influential factors associated with the diagnosis of HB. The findings revealed that with an additional one-year increase in age, patients (OR= 1.017, CI= 1.001, 1.032; $P < 0.05$) were more likely to be diagnosed with chronic HB. When compared to the female patients, the males (OR= 2.040, CI= 1.111, 3.743; $P < 0.05$) were twice more likely to be diagnosed with chronic HB. Comparison made to patients who were children revealed that, traders (OR= 4.459, CI= 1.117, 17.805; $P < 0.05$) and others (OR= 9.879, CI= 2.560, 38.130; $P < 0.05$) were four and nearly ten times likely to have chronic HB respectively. Primary (OR= 2.857, CI= 1.201, 6.797; $P < 0.05$) and SHS (OR= 8.838, CI= 3.381, 23.101; $P < 0.05$) level of education were respectively nearly three and nine times more likely to be diagnosed with chronic HB when compared with patients with no education. The study also established that if the hospitalization duration was increased by a day, patients (OR= 1.040, CI= 1.010, 1.071; $P < 0.05$) were more likely to be diagnosed with CHB than the AHB. It was found that age, gender (male), occupation (traders & others), educational level (primary & SHS) and hospitalization duration were influential factors of HB diagnosis (all $P < 0.05$).

The logistic regression model was given as:

$$\ln(P/(1 - P)) = -3.748 + 0.017 * Age + 0.713 * Gender + 1.495 * Occupation + 1.050 * Educational level + 0.039 * Hospitalization + 0.413 * Location$$

The Logistic regression model for significant factors was given as

$$\ln(P/(1 - P)) = -3.748 + 0.017 * Age + 0.713 * Gender + 1.495 * Occupation + 1.050 * Educational level + 0.039 * Hospitalization$$

Probability Prediction

A respondent of 35 years old man (1), who was a trader (1) with a primary level of education (1) and had been hospitalized for average days of six and a half. The probability of predicting CHB compared with AHB among the patients given the above characteristics would be given as:

$$\begin{aligned} \ln(P/(1 - P)) &= -3.748 + 0.017 * Age + 0.713 * Gender + 1.495 * \\ &Occupation + 1.050 * Educational level + 0.039 * Hospitalization \\ P &= 1/(1 + e^{(-3.748 + 0.017 * Age + 0.713 * Gender + 1.495 * \\ & * Occupation + 1.050 * Educational level + 0.039 * \\ & * Hospitalization)}) \end{aligned}$$

$$P = 1/(1 + e^{(-3.748 + 0.017(35) + 0.713(1) + 1.495(1) + 1.050(1) + 0.039(6.5))})$$

$$P = 1/(1 + e^{(-3.748 + 0.595 + 0.713 + 1.495 + 1.050 + 0.2535)})$$

$$P = 1/(1 + e^{(0.3585)})$$

$$P = 1/(1 + 2.7183)$$

$$P = 1/(3.7183)$$

$$P = 0.2689$$

Based on these clinical and demographic factors, it was determined that the likelihood of this individual having chronic hepatitis B was 26.9%. Even though these characteristics could increase the risk of CHB, the likelihood showed that the risk was low and that there might be other factors at play as well, which could affect the probability either way.

Table 4: Binary Logistic regression showing the factors of Acute and Chronic HB

| Factors | B | P-value | Exp (B) / OR | 95% C.I for Exp (B) | | |
|-----------------|---------|---------|--------------|---------------------|-------|--------|
| | | | | Lower | Upper | |
| Age | 0.017 | 0.027 | 1.017 | 1.001 | 1.032 | |
| Gender | 0.713 | 0.021 | 2.043 | 1.114 | 3.747 | |
| Occupation | traders | 1.495 | 0.034 | 4.459 | 1.117 | 17.805 |
| | others | 2.290 | 0.001 | 9.879 | 2.560 | 38.130 |
| Education | primary | 1.050 | 0.018 | 2.857 | 1.201 | 6.797 |
| | SHS | 2.179 | 0.000 | 8.838 | 3.381 | 23.101 |
| Hospitalization | 0.039 | 0.010 | 1.040 | 1.010 | 1.071 | |
| Location | 0.413 | 0.321 | 1.511 | 0.669 | 3.414 | |
| Constant | -3.748 | 0.000 | 0.024 | | | |

Discussion

Hepatitis B is a significant public health concern that can progress into chronic liver disease, cirrhosis, and hepatocellular carcinoma (Deny et al., 2010). Hepatitis B Virus (HBV) infections can result in a wide range of clinical manifestations. Approximately 90-95% of HBV infections in adults resolve as acute infections with subsequent viral clearance, while 5-10% progress to chronic infections (He et al., 2006; Ganem et al., 2004; Rehmann et al., 2005). A study on both adults and children showed that older individuals, particularly females, are more likely to develop clinical disease compared to younger individuals. In children under 5 years, only 9.5% develop clinical hepatitis after acute HBV infection compared to 33.3% of adults aged 30 years and above (McMahon et al., 1985).

Our study yielded similar findings, showing that age distribution is significant, with a higher proportion of older individuals and females among acute HB patients, and a lower prevalence of chronic HB in children. We also observed that fever, nausea, polydipsia, palpitation, anicteric presentation, anorexia, and itching are less common, while abdominal pain, jaundice, and enlarged liver are more frequent in chronic HB compared to acute HB patients.

In line with our findings, a study on acute HB in pregnant and non-pregnant patients found fever to be associated with HB, while fatigue levels were similar between the two groups (Han et al., 2014). Conversely, Nazarnezhad et al. (2018) found no significant association between fever and HB. Our study also established that levels of AST, viral load, bilirubin, prothrombin time (PT), partial thromboplastin time (PTT), and HBeAg were significantly higher in chronic HB compared to acute HB patients. Serum albumin, abdominal ultrasound (USG), and globin were lower, while liver function test (LFT) and HBsAg levels were higher in acute HB patients. Contrary to our findings, Hugo et al. (2018) detected no HBsAg, indicating no acute or chronic infection.

Our results regarding AST being higher in chronic HB are supported by Sali et al. (2013), though their findings differ in relation to ALT levels, which they found to be higher in chronic HB, unlike our study where ALT, hemoglobin, renal function test (RFT), and total cholesterol levels were similar between acute and chronic HB patients. Additionally, Han et al. (2014) found varied results in relation to HBsAg and AST levels in non-pregnant patients, though they did observe a similar pattern to our study for serum bilirubin levels. Nazarnezhad et al. (2018) also revealed that AST and PT were significant, but ALT and total cholesterol were not, while our study found these factors insignificant. Furthermore, Nazarnezhad et al. (2018) found hemoglobin levels to be significant in chronic HB, while PTT levels were not, in contrast to our findings.

The T-cell-mediated HBV-specific immune response is reflected in elevated serum ALT levels or symptoms (Ratnam et al., 2008). The relatively insignificant clinical symptoms and lower laboratory parameters in acute and chronic HB patients may indicate differences in their immune response. According to acute hepatitis B guidelines, patients who are HBV DNA-positive or HBsAg-positive are considered chronic carriers (CDCP, 2005), and should be counselled accordingly.

Our study found that the prevalence of fever, nausea, polydipsia, palpitation, anicteric symptoms, anorexia, and itching correlated negatively with disease diagnosis, while abdominal pain, jaundice, and enlarged liver correlated positively. This is consistent with Nazarnezhad et al., who found a significant association between anorexia, nausea, enlarged liver, and jaundice in HB patients. Additionally, AST, viral load, HBeAg, PT, PTT, bilirubin, albumin, abdominal USG, and globulin were positively correlated with disease diagnosis, while HBsAg and LFT were negatively correlated. Similar findings were reported by Keshvari et al. (2015) and Li et al. (2018), who also found that HBV DNA and HBsAg correlated significantly with chronic HB patients. However, both studies contradicted our results by indicating that bilirubin and AST levels do not significantly correlate with chronic HB.

Binary logistic regression in this study revealed that age, gender, occupation, educational level, and hospitalization duration are key factors influencing HB diagnosis. Several studies (Alavian et al., 2012; Gheorghe et al., 2013; Khan et al., 2011) support our finding that age is a significant factor, though Yang et al. (2017) disagreed. Regarding gender, our study aligns with previous research (Behal et al., 2008; Deng et al., 2013; Khan et al., 2011; Ochola et al., 2013; Ozer et al., 2011), which found a higher prevalence in males, though other studies (Alavian et al., 2012; Yang et al., 2017) report contrary findings. Our study also found the educational level to be a significant factor, with a decreasing prevalence of HB associated with higher education, possibly due to increased awareness and higher vaccine uptake (Hur et al., 2012). Most patients (two-thirds) had no formal education, suggesting that awareness campaigns should be tailored to less educated populations. Similarly, Yang et al. (2017) identified occupation as a significant factor, with a higher incidence of HB in farming and fishing communities, raising public health concerns.

Discrepancies between studies may be attributed to genetic, sociodemographic, and environmental factors, differences in study design, and patient selection. To our knowledge, this is the first study in the region that has comprehensively reviewed influencing factors and disease manifestations in acute and chronic HB patients with the aim of developing a control strategy. However, data collection was retrospective, introducing the possibility of recall bias, some patients were excluded due to insufficient data and also, data were collected from a single teaching hospital which may not fully represent the broader population.

Conclusions

This study revealed that males as well as adults constitute a higher percentage of patients with CHB and also spent more days on admission. It was established that AHB patients were mostly uneducated and very dominant in the farming/fishing community. Even though a significant number of disease manifestations were associated with CHB patients, laboratory features were predominantly associated with CHB patients while also a greater number of clinical features were significantly associated with AHB patients. Age, gender, occupation, educational level, and hospitalization duration were established as the influencing factors of HB in the study. It is satisfying to note that the findings of this study can be used to create clinical management and awareness programs for hospitals and the public respectively. Hepatitis B education targeted at the uneducated population may be considered as a potential strategy for preventing the menace. A further study may look at clinical and basic studies to validate the findings and also explain the fundamental mechanisms.

Declaration for Human Participants: This study has been approved by Tamale Teaching Hospital and the principles of the Helsinki declaration were followed.

Conflict of Interest: The authors reported no conflict of interest.

Data Availability: All data are included in the content of the paper.

Funding Statement: The authors did not obtain any funding for this research.

References:

1. AASLD. (2011). <https://www.aasld.org/publications/practice-guidelines-0-2011> [Accessed 15 September 2023].
2. Acquaye JK, Mingle JA. (1994). Hepatitis B viral markers in Ghanaian pregnant women. *West African journal of medicine*. 13(3): 134-7.
3. Alavian SM, Tabatabaei SV, Ghadimi T, Beedrapour F, Kafi-Abad SA, Gharehbaghian A, et al. (2012). Seroprevalence of hepatitis B virus infection and its risk factors in the west of Iran: a population-based study. *Int J Prev Med*. 3:770–5.
4. Asadi Noghabi AA, Zandi M, Mehran A, Alavian SM, Dehkordi AH. (2010). The Effect of Education on Quality of Life in Patients under Interferon Therapy. *Hepatitis Monthly*, 10:218-22.
5. Averbhoff F. (2016). Hepatitis B. <http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/hepatitis-B>. [Accessed 23 September 2023].
6. Behal R, Jain R, Behal KK, Bhagoliwal A, Aggarwal N, Dhole TN. (2008). Seroprevalence and risk factors for hepatitis B virus infection among the general population in Northern India. *Arq Gastroenterol*, 45 (2):137–40.
7. Centers for Disease Control and Prevention (2005). Guidelines For Viral Hepatitis Surveillance And Case Management. Atlanta, GA: Centers for Disease Control and Prevention. <http://www.cdc.gov/hepatitis/PDFs/2005Guidlines-Surv-CaseMngmt.pdf>. [Accessed 23 September 2023].
8. Deng QJ, Pan YQ, Wang CY, Li FL, Lv SJ, Hu SY, Ning T, et al. (2013). Prevalence and risk factors for hepatitis B in Hua County, Henan Province. *Beijing Da Xue Xue Bao* 2013;45 (6):965–70.
9. Deny P, Zoulim F. (2010). Hepatitis B virus: from diagnosis to treatment. *Pathol Biol (Paris)* 58:245–53.
10. Dongdem JT, Kampo S, Soyiri IN, Asebga PN, Ziem JB, Sagoe K. (2012). Prevalence of hepatitis B virus infection among blood donors

- at the Tamale Teaching Hospital, Ghana (2009). BMC research notes, 5: 115.
11. Ganem D, Prince AM. (2004). Hepatitis B virus infection-natural history and clinical consequences. *N Engl J Med.* 350:1118–29.
 12. GhanaWeb. (2013). Ghana Rated High Risk for Hepatitis B and [http://www.ghanaweb.com/GhanaHomePage/health/Ghana-rated-high-risk-for-Hepatitis B-C-280781](http://www.ghanaweb.com/GhanaHomePage/health/Ghana-rated-high-risk-for-Hepatitis-B-C-280781). [Accessed 16 September 2023].
 13. Gheorghe L, Csiki IE, Iacob S, Gheorghe C. (2013). The prevalence and risk factors of hepatitis B virus infection in an adult population in Romania: a nationwide survey. *Eur J Gastroenterol Hepatol.* 25(1):56–64.
 14. Han YT, Sun C, Liu CX, Xie SS, Xiao D, Liu L, et al. (2014). Clinical features and outcome of acute hepatitis B in pregnancy. *BMC Infect Dis.* 14:368.
 15. He YL, Zhao YR, Zhang SL, Lim SM. (2006) Host susceptibility to persistent hepatitis B virus infection. *World J Gastroenterol,* 12(30):4788–93.
 16. Howell J, Ladep NG, Lemoine M, Thursz MR, Taylor-Robinson SD. (2014). Hepatitis B in Sub-Saharan Africa. *South Sudan Med J.* 7(3):59–61.
 17. Hugo LG, Lourdes GG, Gabriela EA, Pablo CH, María OP, Deyanira CD, et al. (2018). Hepatitis B seroprevalence in 10-25-year-olds in Mexico - the 2012 national health and nutrition survey (ENSANUT) results, *Human Vaccines & Immunotherapeutics*, DOI: 10.1080/21645515.2018.1533617.
 18. Hur K, Wong M, Lee J, Lee J, Juon HS. (2012). Hepatitis B infection in the Asian and Latino communities of Alameda County, California. *J Community Health* 37 (5):1119–26.
 19. Janahi EM. (2014). Prevalence and risk factors of hepatitis B virus infection in Bahrain, 2000 through 2010. *PLoS One.* 9:e87599.
 20. Keshvari M, Alavian SM, Sharafi H.(2015). Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients. *Jundishapur J Microbiol.* 8(3): e21444.
 21. Khan F, Shams S, Qureshi ID, Israr M, Khan H, Sarwar MT, et al. (2011). Hepatitis B virus infection among different sex and age groups in Pakistani Punjab. *Virol J.* 8:225.
 22. Khosravani A, Sarkari B, Negahban H, Sharifi A, Toori MA, Eilami O. (2012). Hepatitis B Infection among the high-risk population: a seroepidemiological survey in the southwest of Iran. *BMC Infect Dis.* 12:378.

23. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. (2008) Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. *Gastroenterology*, 134(5):1376-84.
24. Lavanchy D. (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepat.* 11(2):97-107.
25. Li MR, Zheng HW, Ma SM, Liu YY, Qie LX, Li JQ, et al. (2018) Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-naïve CHB patients. *J Chin Med Assoc.* 81(12):1052-1059.
26. Martinson FE, Weigle KA, Mushahwar IK, Weber DJ, Royce R, Lemon SM. (1996). Seroepidemiological survey of hepatitis B and C virus infections in Ghanaian children. *Journal of medical virology*, 48(3): 278-83.
27. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP. et al. (1985). Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. *J Infect Dis.* 151:599-603.
28. Mkandawire P, Richmond C, Dixon J, Luginaah IN, Tobias J. (2013). Hepatitis B in Ghana's Upper West Region: a hidden epidemic in need of national policy attention. *Health Place.* 23:89–96. DOI: 10.1016/j.healthplace.2013.06.001.
29. National Institute for Public Health and the Environment (RIVM). Hepatitis B. [http://www.rivm.nl/Onderwerpen/H/Hepatitis B](http://www.rivm.nl/Onderwerpen/H/Hepatitis_B). [Accessed 21 November 2023].
30. National Institute for Public Health and the Environment (RIVM). Nationaal Kompas volksgezondheid: Hepatitis B, 2013. <http://www.nationaalkompas.nl/gezondheid-en-ziekte/ziekten-en-aandoeningen/infectieziekten-en-parasitaire-ziekten/soa/hepatitis-B>. [Accessed 21 November 2023].
31. Nazarnezhad M, Moosavy SH, Davoodian P, Eftekhari E, Nejatizadeh A, Azad M. (2018). The demographic and paraclinical characteristics of patients with hepatitis B presenting to Shahid Mohammadi Hospital and Clinic and other private clinics in Bandar Abbas, Iran. *J Adv Pharm Technol Res.* 9:139-46.
32. Ochola E, Ocama P, Orach CG, Nankanga ZK, Kalyango JN, McFarland W, et al. (2013). High burden of hepatitis B infection in Northern Uganda: results of a population-based survey. *BMC Public Health*, 13:727.
33. Owusu-Ansah T. (2014). *Viral Hepatitis in Ghana: The Role of the Government*

- <http://www.ghanaweb.com/GhanaHomePage/NewsArchive/Viral-Hepatitis-In-Ghana-The-Role-Of-The-Government-222118>
[Accessed 15 September 2023].
34. Ozer A, Yakupogullari Y, Beytur A, Beytur L, Koroglu M, Salman F, et al. (2011). Risk factors of hepatitis B virus infection in Turkey: a population-based, case-control study: risk factors for HBV infection. *Hepat Mon.* (4);11:263–8.
 35. Ratnam D, Visvanathan K. (2008). New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response. *Hepato Int.* 2(1):12–18.
 36. Rehermann B, Nascimbeni M. (2005). Immunology of hepatitis B virus and hepatitis C virus infection. *Nat Rev Immunol.* 5:215–29.
 37. Sali S, Alavian SM, Foster GR, Keyvani, H, Mehrnoosh L, Mohammadi N. (2013). Influencing Factors on the Outcome and Prognosis of Patients With HBV Infection: Seven Years Follow-up. *Hepatitis Monthly*, 13:e8743. <http://doi.org/10.5812/hepatmon.8743>.
 38. Salimi N, Jahan A, Hazrati S. (2014). Evaluation of the prevalence of hepatitis B surface antigen and its related factors in pregnant women referring to health centres in Ardabil city in 2009. *Health J.* 5:58-248.
 39. Teye J. (2015). Ghana risks losing productive youth to Hepatitis-Medical Professor.
<http://www.myjoyonline.com/lifestyle/2015/September-15th/ghana-risks-losing-productive-youth-to-hepatitis-medical-professor.php>.
[Accessed 15 September 2019].
 40. van Ballegooijen WM, van Houdt R, Bruisten SM, Boot HJ, Coutinho RA, Wallinga J. (2009). Molecular sequence data of hepatitis b virus and genetic diversity after vaccination. *American Journal of Epidemiology*, 170(12):1455–1463.
 41. van de Laar MJW, Beuker RJ, Rijlaarsdam J, van Duynhoven YTHP. (2000). Hepatitis B. Technical Report 441500 011, National Institute for Public Health and the Environment (RIVM).
 42. van Houdt R, Bruisten SM, Speksnijder AG, Prins M. (2012). Unexpectedly high proportion of drug users and men having sex with men who develop chronic hepatitis B infection. *Journal of Hepatology*, 57(3):529–533.
 43. Walana W, Hokey P, Ahiaba S. (2014). Sero-Prevalence of Hepatitis B Virus Infection among Blood Donors: A Retrospective Study in the Kintampo Municipal Hospital, Ghana. *Open Journal of Medical Microbiology*, 4: 64-9.
 44. World Health Organization. (2002). Global alert and response (gar): Hepatitis B,

- <http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index3.html> [Accessed 21 November 2023].
45. World Health Organization. (2013). Fact sheet no 204: Hepatitis B. <http://www.who.int/mediacentre/factsheets/fs204/en/> [Accessed 21 November 2019].
46. Yang S, Ding C, Cui Y, Wu J, Yu C, Chen P, et al. (2017). Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study. *BMJ Open*, 7(4):e014947. DOI:10.1136/bmjopen-2016- 014947